dc.contributor.author | Turner, N | |
dc.contributor.author | Huang-Bartlett, C | |
dc.contributor.author | Kalinsky, K | |
dc.contributor.author | Cristofanilli, M | |
dc.contributor.author | Bianchini, G | |
dc.contributor.author | Chia, S | |
dc.contributor.author | Iwata, H | |
dc.contributor.author | Janni, W | |
dc.contributor.author | Ma, CX | |
dc.contributor.author | Mayer, EL | |
dc.contributor.author | Park, YH | |
dc.contributor.author | Fox, S | |
dc.contributor.author | Liu, X | |
dc.contributor.author | McClain, S | |
dc.contributor.author | Bidard, F-C | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2023-05-30T12:16:25Z | |
dc.date.available | 2023-05-30T12:16:25Z | |
dc.date.issued | 2023-03-01 | |
dc.identifier.citation | Future Oncology, 2023, 19 (8), pp. 559 - 573 | en_US |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5809 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2022-1196 | |
dc.description.abstract | ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Camizestrant is a next-generation oral selective estrogen receptor degrader (SERD) that in a phase II study significantly improved progression-free survival (PFS) over fulvestrant (also a SERD) in ER+/HER2- ABC. SERENA-6 (NCT04964934) is a randomized, double-blind, phase III study evaluating the efficacy and safety of switching from an AI to camizestrant, while maintaining the same CDK4/6i, upon detection of ESR1m in circulating tumor DNA before clinical disease progression on first-line therapy for HR+/HER2- ABC. The aim is to treat ESR1m clones and extend the duration of control of ER-driven tumor growth, delaying the need for chemotherapy. The primary end point is PFS; secondary end points include chemotherapy-free survival, time to second progression event (PFS2), overall survival, patient-reported outcomes and safety. | |
dc.format | Print-Electronic | |
dc.format.extent | 559 - 573 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | FUTURE MEDICINE LTD | en_US |
dc.relation.ispartof | Future Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | ESR1 mutation | |
dc.subject | advanced breast cancer | |
dc.subject | camizestrant | |
dc.subject | circulating tumor DNA | |
dc.subject | endocrine therapy resistance | |
dc.subject | hormone-receptor-positive breast cancer | |
dc.subject | selective estrogen receptor degrader | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Aromatase Inhibitors | |
dc.subject | Breast Neoplasms | |
dc.subject | Clinical Trials, Phase III as Topic | |
dc.subject | Fulvestrant | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.subject | Receptor, ErbB-2 | |
dc.subject | Receptors, Estrogen | |
dc.title | Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-03-01 | |
dc.date.updated | 2023-05-30T12:14:14Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.2217/fon-2022-1196 | en_US |
rioxxterms.licenseref.startdate | 2023-03-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37070653 | |
pubs.issue | 8 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology | |
pubs.publication-status | Published | |
pubs.publisher-url | http://dx.doi.org/10.2217/fon-2022-1196 | |
pubs.volume | 19 | |
icr.researchteam | Molecular Oncology | en_US |
dc.contributor.icrauthor | Turner, Nicholas | |
icr.provenance | Deposited by Mr Arek Surman on 2023-05-30. Deposit type is initial. No. of files: 1. Files: fon-2022-1196.pdf | |